Ligand Pharmaceuticals

Castle Creek Biosciences is focused on developing and commercializing novel, personalized gene therapies for rare skin and connective tissue disorders with high unmet need. It was founded in 2015 and headquartered in Pennsylvania, United States.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

invIOs is a private biotechnology company that specializes in the discovery and development of next-generation cancer therapies that empower and educate the immune system to fight cancer.

Agenus Inc. is a clinical-stage immuno-oncology company focused on the discovery, development, and commercialization of innovative immunotherapies and vaccines for cancer and infectious diseases. Based in Lexington, Massachusetts, the company aims to activate the immune system to recognize and combat cancer cells through a diverse portfolio that includes checkpoint antibodies, tumor microenvironment modifiers, and vaccine adjuvants. Agenus utilizes its proprietary Retrocyte Display platform for antibody discovery and develops a range of therapeutic candidates, including monoclonal antibodies and vaccines targeting various tumor-specific neo-epitopes. The company has several products in clinical trials, including CTLA-4 and PD-1 antagonists, and collaborates with notable partners such as Incyte Corporation and Merck Sharpe & Dohme to advance its immuno-oncology therapies. Founded in 1994, Agenus continues to build its capabilities in research, development, and manufacturing within the field of immunotherapy.

XCella Biosciences is an antibody discovery company that offers a platform that can screen single B cells. It develops therapeutics to transform patient outcomes with protein engineering and disruptive technology. xCella's xPloration is an integrated hardware and software platform that enables high dimensional measurement and analysis of genotype, phenotype, and cellular functions at the single-cell level, millions of cells at a time. The company was founded in 2015 and based in Menlo Park, California.

Headquartered in San Diego, California, Pfēnex Inc. is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars. The Company's core technology, Pfēnex Expression Technology™, is a cutting edge protein expression platform that utilizes the BSL-1 microorganism Pseudomonas fluorescens. Pfēnex Expression Technology™ combines an extensive toolbox of expression components with a robotically enabled high throughput parallel strain screening technology, delivering unprecedented speed and success in identifying protein production strains expressing high titers of soluble active protein.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Technology Platform. Icagen’s extensive biological capability focused on ion channels, transporters and x-ray fluorescence, along with a strong track record in novel drug discovery from screening to lead optimization. Ion channels are key components in a wide variety of biological processes that involve rapid changes in cells and have broad therapeutic applicability including cancer, metabolic disease, pain, neurological diseases, infectious diseases and others. Roche Collaboration to develop and commercialize therapies for neurological diseases. The collaboration provides research funding, potential milestone payments of up to $274 million and tiered royalty payments should a drug be commercialized. Cystic Fibrosis Foundation (CFF) Collaboration to discover therapeutics to treat patients with cystic fibrosis caused by specific genetic mutations. The CFF collaboration allows for up to $11 million in research funding, milestone payments of up to $59 million and tiered royalties on sales, should a product be commercialized. Proprietary Service Unit to Drive New Collaborations and Revenue, including a 32-person R&D team based in Raleigh, N.C., now known as Icagen, a Ligand Company, focused on drug discovery of ion channels and transporters. Icagen provides Ligand with an East Coast operation to efficiently serve partners and brings a portfolio of current or recent/active collaboration agreements with over 30 biopharma companies plus an ongoing business development pipeline. Novel, Unpartnered Programs that include six preclinical-stage assets applicable to a range of therapy areas including diabetes, Parkinson’s disease, pain and other disorders.

Ab Initio Biotherapeutics, Inc. is a biopharmaceutical company focused on the development of protein therapeutics, specifically targeting G-protein coupled receptors (GPCRs) through its proprietary antigen discovery platform. This platform enables the identification of both activating and inactivating antibodies and facilitates the generation of therapeutic antibodies against challenging cellular targets. The company's research encompasses various therapeutic areas, including cancer immunotherapy, as well as treatments for neurological, cardiovascular, endocrine, and gastrointestinal disorders. Established in 2015 and based in South San Francisco, California, Ab Initio Biotherapeutics operates as a subsidiary of Ligand Pharmaceuticals, maintaining a strategic collaboration with Pfizer to enhance its drug development initiatives.

Dianomi Therapeutics is a biopharmaceutical company based in Madison, Wisconsin, founded in 2017. The company specializes in developing innovative therapeutics using its proprietary mineral coated microparticle (MCM) technology, which enhances the delivery and efficacy of both large and small molecules targeting inflammatory diseases, particularly osteoarthritis and rheumatoid arthritis. Dianomi's MCM system addresses challenges faced by traditional drug delivery methods by enabling sustained release of active biologics, thereby improving patient outcomes through enhanced safety, efficacy, and duration of therapeutic effects. The company collaborates with biotech and pharmaceutical firms to advance its treatment solutions in the field of inflammatory disease management.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Vernalis Limited is a commercial stage pharmaceutical company based in Cambridge, United Kingdom, focused on the research, development, and commercialization of products for various medical disorders. The company offers several products, including Tuzistra XR for the U.S. cough-cold market, Moxatag, a once-daily amoxicillin formulation for treating tonsillitis and pharyngitis, and frovatriptan for migraine relief. Vernalis also engages in licensing agreements to develop and commercialize additional products in the cough-cold sector. The company integrates advanced research techniques, including structural biology and medicinal chemistry, to facilitate drug discovery across both established and novel therapeutic targets. Vernalis operates as a subsidiary of Ligand Pharmaceuticals and has been active since its incorporation in 1988.

Crystal Bioscience is a privately-held company that was founded in 2008 to develop a therapeutic antibody discovery engine using chickens. Its platform relies on the large phylogenetic distance between mammals and birds to generate a diverse array of antibodies to human targets that have proven intractable in mammalian and other discovery platforms.

OMT

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, that develops innovative therapies for metabolic and endocrine disorders. Its lead drug candidate, VK2809, is an orally available selective agonist of the thyroid hormone receptor beta, currently undergoing Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis. Another key candidate, VK5211, is a non-steroidal selective androgen receptor modulator being tested in Phase II trials to aid recovery from non-elective hip fracture surgery. Additionally, the company is advancing VK0612, a drug candidate for type 2 diabetes, and VK0214, targeted for X-linked adrenoleukodystrophy. Viking Therapeutics emphasizes the development of first-in-class and best-in-class therapies, leveraging its expertise in metabolism to address significant unmet medical needs.

CyDex Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing drugs that overcome the limitations of existing therapies. The company utilizes its proprietary drug formulation technology, specifically Captisol, a type of cyclodextrin, to create a diverse portfolio of product candidates. Notable products include Geodon IM and Abilify Injection IM for bipolar disorder and schizophrenia, Vfend IV for antifungal treatments, and Cerenia for canine motion sickness. Additionally, CyDex is developing medications such as Fosphenytoin IV and IM for status epilepticus, Melphalan IV for multiple myeloma, and several others targeting conditions like epilepsy, arrhythmia, asthma, and allergic rhinitis. The company also outlicenses its technology to third parties for their product development needs. Founded in 1993 and based in Lenexa, Kansas, CyDex Pharmaceuticals was formerly known as CyDex, Inc. before its name change in 2007.

Neurogen Corporation is a drug development company historically focusing on small-molecule drugs to improve the lives of patients suffering from psychiatric and neurological disorders with significant unmet medical need. Neurogen has conducted its drug development independently and, when advantageous, collaborated with world-class pharmaceutical companies to access additional resources and expertise.

Metabasis is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs by applying its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways. The Company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' product pipeline represents candidates indicated for the treatment of metabolic diseases such as hyperlipidemia and diabetes, among others. Additionally, our pipeline includes drug candidates for the treatment of liver diseases such as hepatitis and primary liver cancer which the company plans to license to companies focused on these areas. All of our product candidates were developed internally using proprietary technologies including our NuMimetic and HepDirect technologies.

Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company's products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. Pharmacopeia has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Cranbury, New Jersey. As of December 23, 2008, Pharmacopeia, Inc. operates as a subsidiary of Ligand Pharmaceuticals Inc.